Slide 1: H1 2024 Results
H1 2024 Results Matthias Gaertner, CEO Falk Neukirch, CFO August 13, 2024
Slide 2: Agenda
1. Executive summary 2. Financial overview 3. Guidance 2024, growth story 4. Appendix 2
Slide 3: Highlights H1 2024
Executive summary Highlights H1 2024 Solid Group financials for H1 2024 driven by PS business; • Ceban fully consolidated since June under new segment International Financials • Revenue increase of 6.3% to c. €907m; EBITDA pre increased by 7.3% to c. €31m - including Ceban’s contribution for one mon
Slide 4: Snapshot Ceban Pharmaceuticals
Executive summary Snapshot Ceban Pharmaceuticals Ceban Pharmaceuticals • Leading full-service compounding services platform • Diversified business model covering the full compounding value chain: Founded Headquarters Employees · Compounding Services (non-sterile and sterile) 2004 Breda, Netherlands
Slide 5: Excellent geographic coverage through a market leading German and strong Northwestern European network
Executive summary Excellent geographic coverage through a market leading German and strong Northwestern European network With the acquisition of Hamburg Ceban, Medios will have a leading position in Osnabrueck Berlin (HQ) Specialty Pharma compounding Bonn in Europe Aschaffenburg Mannheim Saarlouis M
Slide 6: QoQ – Revenue and EBITDA pre growth
Executive summary QoQ – Revenue and EBITDA pre growth Revenue (€m) EBITDA pre¹ €m 17.2 16.1 490 15.3 15.0 15.1 441 456 451 14.1 14.3 14.1 14.3 419 431 422 393 399 399 11.1 2.7 3.6 3.6 3.6 3.5 3.6 3.4 3.5 3.3 3.3 3.0 3.6 3.6 3.4 3.4 3.2 3.0 2.8 2.8 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q
Slide 7: YoY: Continuous revenue growth
Executive summary YoY: Continuous revenue growth Revenue in €m EBITDA pre¹ in €m 6.3% 7.3% 854 907 29.0 31.1 H1 2023 H1 2024 H1 2023 H1 2024 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock option
Slide 8: Agenda
1. Executive summary 2. Financial overview 3. Guidance 2024, growth story 4. Appendix 8
Slide 9: H1 2024 – Solid Group financials and strong operating CF
Financial overview H1 2024 – Solid Group financials and strong operating CF In € million H1 2024 H1 2023 ∆ in % Comments Revenue 907.3 853.5 6.3% Financials including the strong contribution of Ceban (new Gross profit1 60.4 54.4 segment: International) for one month 11.0% gross margin in % 6.7% 6.4%
Slide 10: H1 2024 – Ongoing organic and inorganic revenue growth
Financial overview H1 2024 – Ongoing organic and inorganic revenue growth; strong one month Ceban contribution YoY revenue in €m H1 23 Organic Inorganic H1 24 Comments Pharmaceutical Supply (PS) 734.1 53.8 - 787.9 • Ceban acquisition led to revenue contribution for June 2024 in the amount of €11.6m
Slide 11: H1 2024 – Ongoing organic and inorganic EBITDA pre growth
Financial overview H1 2024 – Ongoing organic and inorganic EBITDA pre growth – strong one month Ceban contribution EBITDA pre1 in €m H1 23 Organic Inorganic H1 24 Comments Pharmaceutical Supply (PS) 19.9 3.0 - 22.9 • EBITDA pre of PS grew organically (€3.0m) Patient-Specific Therapies (PST) • Intern
Slide 12: H1 2024 – Strong PS business; PST impacted by regulatory effects
Financial overview H1 2024 – Strong PS business; PST impacted by regulatory effects; Internation one month only Pharmaceutical Patient-specific International Internal Services IFRS consolidation Group Supply ‘PS‘ Therapies ‘PST’ YoY in € million H1 24 H1 23 H1 24 H1 23 H1 24 H1 23 H1 24 H1 23 H1 24
Slide 13: Status Debt-Financing
Financial overview Status Debt- Financing • Revolving credit facility of up to €75m available to finance growth; restricting maximum net leverage • Fully drawn bridge-loan over €200m, term (including extension option) June 2025 • Net debt as of 30 June 2024 appr. €150m • Bridge-loan follow-up financ
Slide 14: Agenda
1. Executive summary 2. Financial overview 3. Guidance 2024, growth story 4. Appendix 14
Slide 15: New Group: Significant revenue & EBITDA pre increase expected
Guidance 2024 confirmed Guidance 2024 & growth story New Group: Significant revenue & Revenue (€bn) At least 1.90 - 2.10 EBITDA pre increase expected + 5.6% Guidance confirmed: • One month later than planned consolidation of ~1.8 Ceban as of June 1, 2024 (previously as of May 1, 2024 expected); regu
Slide 16: Goals: We want to continue growing
Guidance 2024, growth story Goals: We want to continue growing Strengthening the Expansion of Diversification: core business in manufacturing in personalized Germany Europe therapies Expansion and optimi- Setting-up the European Positioning as a reliable zation of manufacturing platform for Specialt
Slide 17: Internationalization: From German market leader to international player
Guidance 2024, growth story Internationalization: From German market leader to international player... Hamburg Berlin (HQ) Osnabruck Berlin With the acquisition of Ceban, Medios will become a leading position in the field of Specialty Pharma Compounding in Bonn Europe Aschaffenburg Mannheim Saarloui
Slide 18: Market entry into Advanced Therapy field
Strategy Market entry into Advanced Therapy field Advanced Therapy market continues to be promising Establishment of an organisational structure Appointment of Dr A Schmiede VP Advanced Therapies Ongoing market analysis Leveraging the existing decentralized GMP manufacturing and logistic infrast
Slide 19: Agenda
1. Executive summary 2. Financial overview 3. Guidance 2024, growth story 4. Appendix 19
Slide 20: Ceban: Transformative and value enhancing acquisition
Executive summary - Events after the consolidated balance sheet date Ceban: Transformative and value enhancing acquisition • First step in Medios internationalization Internationalization • Immediate market entry into three European countries: NL, BE, ES • A leading position in compounding in Northw
Slide 21: Ceban operates synergistic positions across the compounding value chain
Ceban – Deep dive Ceban operates synergistic positions across the compounding value chain Compounding Services API Services Pharmacies • Tailor-made medication • Sourcing, repacking and • 23 owned pharmacies across compounded at GMP-compliant distributing APIs and excipients the Netherlands under th
Slide 22: Q2 2024 - Driven by acquisition of Ceban
Financial overview Q2 2024 - Driven by acquisition of Ceban YoY Revenue in €m Q2 23 Organic Inorganic Q2 24 Comments Pharmaceutical Supply (PS) 366.0 20.9 - 386.9 • Inorganic growth driven by Ceban acquisition Patient-Specific Therapies (PST) 56.0 -3.6 - 52.5 • Organic growth 4.1% International 11.6
Slide 23: Q2 2024 – Impacted by integration of Ceban
Financial overview Q2 2024 – Impacted by integration of Ceban YoY EBITDA pre1 in €m Q2 23 Organic Inorganic Q2 24 Comments Pharmaceutical Supply (PS) 9.8 2.1 - 11.8 • Successful integration of Ceban led to EBITDA pre1 contribution of €2.7m Patient-Specific Therapies (PST) 6.0 -1.0 - 4.9 • Services r
Slide 24: Key figures (1/2)
Appendix Key figures (1/2) in € thousand H1 2024 H1 2023 ∆ in % Q2 2024 Q2 2023 ∆ in % Revenue 907,261 853,517 6.3% 451,036 422,278 6.8% Pharmaceutical Supply 787,930 734,146 7.3% 386,888 366,002 5.7% Patient-Specific Therapies 107,517 118,948 -9.6% 52,456 56,012 -6.3% International 11,584 - - 11,58
Slide 25: Key figures (2/2)
Appendix Key figures (2/2) in € thousand H1 2024 H1 2023 ∆ in % Q2 2024 Q2 2023 ∆ in % Earnings per share (in €) Undiluted 0.27 0.39 -30.8% 0.10 0.19 -47.4% Diluted 0.27 0.39 -30.8% 0.10 0.19 -47.4% Investments (CAPEX) 1784 547 >100% 1,318 272 >100% Cash flow from operating activities 34,041 -75,170
Slide 26: Q2 2024 – Strong financials
Appendix Q2 2024 – Strong financials Pharmaceutical Patient-specific International Internal Services IFRS consolidation Group Supply ‘PS‘ Therapies ‘PST’ YoY in € million Q2 24 Q2 23 Q2 24 Q2 23 Q2 24 Q2 23 Q2 24 Q2 23 Q2 24 Q2 23 Q2 24 Q2 23 Total segment revenue 422.2 398.9 56.2 64.5 11.6 3.0 2.4
Slide 27: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 claudia.nickolaus@medios.group
Slide 28: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 29: H1 2024 Results
H1 2024 Results Matthias Gaertner, CEO Falk Neukirch, CFO August 13, 2024